Summit Therapeutics Inc. 8-K

What Happened
Summit Therapeutics Inc. filed a Form 8-K reporting new clinical data releases related to ivonescimab. On May 30, 2026 the company issued a press release on results from AK112-206, a global, open-label, multicenter Phase II study in first‑line metastatic colorectal cancer co‑sponsored with partner Akeso, Inc. On May 31, 2026, Summit noted that Akeso published results from HARMONi-6 (AK112-306), a single‑region, multicenter Phase III study conducted in China with data generated and analyzed exclusively by Akeso. Summit also posted slides for a conference call scheduled for 7:00 a.m. ET on June 1, 2026 to discuss the data.

Key Details

• AK112-206: global, open‑label, multicenter Phase II study in first‑line metastatic colorectal cancer; co‑sponsored by Summit and Akeso.
• HARMONi-6 (AK112-306): single‑region, multicenter Phase III study in China; sponsored and analyzed solely by Akeso (reported May 31, 2026).
• Summit attached the May 30 and May 31 press releases and June 1 presentation slides to the 8-K as exhibits.
• The Form 8-K was signed June 1, 2026 by Manmeet S. Soni, Summit’s COO, CFO and Director.

Why It Matters
These filings provide investors with newly released clinical data for ivonescimab from both a Summit‑co‑sponsored Phase II trial and an Akeso‑sponsored Phase III trial. The information and the company’s presentation slides (and accompanying conference call) are the primary sources for assessing recent clinical progress and near‑term development updates; investors should review the press releases and slides for specific efficacy/safety details and any implications for regulatory or development timelines.